Nonhealing Venous Leg Ulcers Treated With a Standard of Care (SoC) Alone or Standard of Care and Dehydrated Human Placenta Tissue (dHPT) With Crossover
Part of paid clinical trials in Rocky Mount, North Carolina.
- Sponsor
- Cellution Biologics
- Study ID
- NCT07230340
- Phase
- PHASE4
- Status
- Enrolling By Invitation
Conditions
- Venous Leg Ulcer (VLU)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Amnion-Intermediate-Chorion — OTHERDehydrated human placental multilayer allograft derived from donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.
- Standard of Care (SOC) — PROCEDUREStandard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.
Study Details
The purpose of this study is to determine how well our dHPT (Dehydrated Human Placental Tissue) Product and Standard of Care work when compared to Standard of Care alone in achieving complete closure of venous leg ulcers.
Key Dates
- First listed
- Nov 17, 2025
- Start date
- Feb 4, 2026
- Status verified
- Aug 2026
- Primary completion
- Aug 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 70 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Standard of CareBeginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 10 weeks, whichever occurs first.
- Experimental: AIC and Standard of CareParticipants with a venous leg ulcer (VLU) will receive treatment with an Amnion-Intermediate-Chorion (AIC) sheet product, a dehydrated multilayer human placental tissue derived from donated human tissue, and weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 10 weeks, whichever occurs first.
Primary Outcome Measure
Percentage of Venous Leg Ulcers with Complete Wound Closure [ Time Frame: 1-10 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Foot & Ankle Institute of the Carolinas | Rocky Mount | North Carolina | 27804 | - |
Find similar trials in Rocky Mount, NC
By research site
Related Studies
- A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TLPHASE4 · Recruiting · HealthTech Wound Care · DeLand, Florida
- A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)PHASE3 · Recruiting · MediWound Ltd · Fresno, California
- Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg UlcersPHASE4 · Recruiting · Kerecis Ltd. · Monroeville, Pennsylvania
- Evaluating the Durability of Closure for Venous Leg UlcersRecruiting · Kerecis Ltd. · Monroeville, Pennsylvania